It may only cost $300-$500m upfront to buy us out, but neither Fujifilm nor Sumitomo have the resources to develop everything in the pipeline over the next decade. This is where a joint T/O could work.
Let's just hypothetically say Fujifilm only wants to develop:
- GvHD
- CLI
- Diabetic Wounds
While Sumitomo only wants to develop:
- Asthma
- Heath Attack
- Coronary Artery Disease
But both want to develop:
- Brain Cancer
- Acute Respiratory Disease Syndrome
People are talking about sub-licensing as being the "...structural aspects of the GvHD license agreement."
Could it be licensing the the tech to two companies that is being negotiated with WARF?
Fuji WARF and the extension, page-14
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.005(2.44%) |
Mkt cap ! $36.11M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 20.0¢ | 19.0¢ | $19.42K | 101.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8208 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 9829 | 1 |
View Market Depth
| Last trade - 15.42pm 03/09/2024 (20 minute delay) ? |
| CYP (ASX) Chart |